Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioTime Starts US-China Test of Cancer Diagnostic

publication date: Jan 29, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioTime, a California stem cell company, has begun a concurrent study of its bladder cancer diagnostic test in the US and China. OncoCyte, Biotime’s cancer-focused subsidiary, will compare standard-of-care diagnostic technologies (cellular microscopic analysis of the urine samples) to OncoCyte's PanC-Dx™ biomarkers for relative efficacy. OncoCyte has identified the PanC-Dx biomarkers as being abnormally activated in cancer or tumor cells, many of which were not previously associated with cancer. More details....

Stock Symbol: (NYSE: BTX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...